Key Takeaways:
- Law firm KSF is investigating the proposed sale of Avanos Medical.
- The inquiry focuses on the adequacy of the $25.00 per share offer.
- Shareholders face uncertainty over the deal's final price and completion.
Back
Back
Avanos Medical sale investigated for fairness at $25 per share
Kahn Swick & Foti is investigating the proposed $25.00 per share cash sale of Avanos Medical to American Industrial Partners affiliates.
"KSF is seeking to determine whether this consideration and the process that led to it are adequate for Avanos shareholders," the firm, led by former Louisiana Attorney General Charles C. Foti, Jr., said in a statement.
The proposed transaction would pay investors $25.00 in cash for each share of Avanos they own. The investigation by KSF centers on whether the board of directors is fulfilling its fiduciary duties to maximize shareholder value.
The probe introduces significant risk to the deal's closure, potentially leading to a revised, higher offer or a complete collapse of the transaction. This uncertainty could drive volatility in Avanos Medical's stock price in the near term.
The investigation announced by Kahn Swick & Foti targets the financial terms and the strategic process behind the planned acquisition of Avanos Medical by private equity firm American Industrial Partners. Such investigations are common in M&A deals and can act as a catalyst for revised terms if the initial offer is found to undervalue the company.
The outcome of this investigation could materially impact the return for Avanos shareholders. Investors will be closely watching for any further announcements from KSF or a response from the Avanos board regarding the valuation.
This article is for informational purposes only and does not constitute investment advice.
Features
Resources
© 2026 Finture Development Limited. All rights reserved